SCHEMBL29488484

SCHEMBL29488484

O=C(CCCC/C=C(\COc1cccc2ccccc12)C(=O)NC1CCN(Cc2ccccc2)C1)NO

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RX3 P56373 1/20 0.55
▸ SIGMAR1 Q99720 4/20 0.45
▸ GCGR P47871 1/20 0.44
▸ DRD4 P21917 4/20 0.43
▸ DRD2 P14416 3/20 0.43
▸ HDAC1 Q13547 4/20 0.43
▸ HDAC6 Q9UBN7 4/20 0.43
▸ HDAC3 O15379 3/20 0.43
▸ HDAC4 P56524 3/20 0.43
▸ HDAC7 Q8WUI4 3/20 0.43
▸ HDAC2 Q92769 3/20 0.43
▸ HDAC10 Q969S8 3/20 0.43
▸ HDAC11 Q96DB2 3/20 0.43
▸ HDAC8 Q9BY41 3/20 0.43
▸ HDAC9 Q9UKV0 3/20 0.43
▸ HDAC5 Q9UQL6 3/20 0.43
▸ BACE1 P56817 1/20 0.42
▸ CCR2 P41597 1/20 0.42
▸ EHMT1 Q9H9B1 1/20 0.41
▸ DRD3 P35462 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1305009 1.00 P2RX3 (0.55) P2RX3SIGMAR1GCGRDRD4DRD2
SCHEMBL1305012 1.00 P2RX3 (0.55) P2RX3SIGMAR1GCGRDRD4DRD2
SCHEMBL1307324 0.93 P2RX3 (0.54) P2RX3SIGMAR1GCGRDRD4DRD2
SCHEMBL1307322 0.93 P2RX3 (0.54) P2RX3SIGMAR1GCGRDRD4DRD2
SCHEMBL1307946 0.91 P2RX3 (0.52) P2RX3SIGMAR1GCGRDRD4DRD2
SCHEMBL1307948 0.91 P2RX3 (0.52) P2RX3SIGMAR1GCGRDRD4DRD2
SCHEMBL1306538 0.91 P2RX3 (0.44) P2RX3HDAC1HDAC6HDAC3HDAC4
SCHEMBL1306531 0.91 P2RX3 (0.44) P2RX3HDAC1HDAC6HDAC3HDAC4
SCHEMBL29488459 0.91 P2RX3 (0.44) P2RX3HDAC1HDAC6HDAC3HDAC4
SCHEMBL1307111 0.88 P2RX3 (0.42) P2RX3HDAC1HDAC6HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114340672-A Pharmaceutical composition comprising an HDAC inhibitor and an anti-PD 1 antibody or an anti-PD-L1 antibody 晶体基因技术株式会社 2022-04-12 — — CN claimed
CN-112930177-B Pharmaceutical compositions containing alkylcarbamoyl naphthoyl octenoyl hydroxyamide phosphate, tartrate or combinations thereof and methods of making the same 晶体基因技术株式会社 2024-01-30 — — CN disclosed
EP-4155292-A1 METHOD FOR PRODUCING PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE Crystalgenomics, Inc. (KR) 2023-03-29 — — EP disclosed
CN-114340672-A Pharmaceutical composition comprising an HDAC inhibitor and an anti-PD 1 antibody or an anti-PD-L1 antibody 晶体基因技术株式会社 2022-04-12 — — CN disclosed
CN-110740989-B Pharmaceutically acceptable salts of alkylcarbamoylnaphthoxyoctenoylhydroxyamides or derivatives thereof and process for preparing the same 晶体基因技术株式会社 2022-03-08 — — CN disclosed
Send feedback